Butylparaben

Butylparaben

SCHEMBL761983

CCCCOC(=O)c1ccc(O)cc1.[KH]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 10/20 0.96
TSHR P16473 3/20 0.96
LMNA P02545 2/20 0.96
CYP1A2 P05177 2/20 0.96
CYP2C19 P33261 2/20 0.96
SMN1; SMN2 Q16637 2/20 0.96
CYP2D6 P10635 1/20 0.96
MAPK1 P28482 1/20 0.96
NR1H2 P55055 1/20 0.96
RNASEL Q05823 1/20 0.96
ALDH1A1 P00352 2/20 0.77
CHRM1 P11229 1/20 0.77
SLC6A2 P23975 1/20 0.77
KDR P35968 1/20 0.77
TDP1 Q9NUW8 1/20 0.77
CYP3A4 P08684 1/20 0.70
CYP2C9 P11712 1/20 0.70
PDE4D Q08499 1/20 0.70
CA12 O43570 1/20 0.65
CA1 P00915 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butylparaben SCHEMBL5789201 0.98 ESR1 (1.00) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL3647 0.98 ESR1 (1.00) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL344001 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL29376702 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL27203944 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL5152448 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL2325184 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL9172319 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL29377478 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19
Butylparaben SCHEMBL27996201 0.96 ESR1 (0.96) ESR1TSHRLMNACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608929-A1 BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT LyondellBasell Advanced Polymers Inc. (US) 2025-09-03 EP claimed
US-12338390-B2 Bridging particle and fluid loss control agent LYONDELLBASELL ADVANCED POLYMERS INC. (US) 2025-06-24 US claimed
US-20240228859-A9 BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT LYONDELLBASELL ADVANCED POLYMERS INC. (US) 2024-07-11 US claimed
WO-2024091462-A1 BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT LYONDELLBASELL ADVANCED POLYMERS INC. (US) 2024-05-02 WO claimed
US-20240132772-A1 BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT LYONDELLBASELL ADVANCED POLYMERS INC. (US) 2024-04-25 US claimed
US-7128923-B2 Preserved and stable compositions containing peptide copper complexes and method related thereto PROCYTE CORPORATION (US) 2006-10-31 US claimed
WO-2026090227-A1 ORAL CARE STRIP COLGATE-PALMOLIVE COMPANY (US) 2026-04-30 WO disclosed
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent SYMRISE AG (DE) 2026-02-12 US disclosed
US-12545860-B2 Mannanase variants BASF SE (DE) 2026-02-10 US disclosed
US-20260034042-A1 Composition with Improved SPF and UVA Photoprotection SYMRISE AG (DE) 2026-02-05 US disclosed
EP-4676428-A1 LIQUID UV FILTER COMPOSITION CONTAINING DIOLS Symrise AG (DE) 2026-01-14 EP disclosed
EP-4676433-A1 LIQUID UV FILTER CONCENTRATE Symrise AG (DE) 2026-01-14 EP disclosed
EP-4608929-A1 BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT LyondellBasell Advanced Polymers Inc. (US) 2025-09-03 EP disclosed
US-20030185777-A1 Anhydrous antiperspirant composition containing polysaccharides HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 2003-10-02 US disclosed
US-6576298-B2 For use in container filling or packaging operations for foods (frozen), beverages ECOLAB INC. 2003-06-10 US disclosed
CN-1385457-A Gel composition PANRICO PARTNERSHIP INC (US) 2002-12-18 CN disclosed
US-20020115573-A1 Lubricants formulated and qualified for contact with food compositions and related business methods ECOLAB USA INC. 2002-08-22 US disclosed
CN-1348815-A Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use TIANJIN TIANSHILI PHARMACEUTIC (CN) 2002-05-15 CN disclosed
US-20020051850-A1 Lubricant qualified for contact with a composition suitable for human consumption including a food, a conveyor lubrication method and an apparatus using droplets or a spray of liquid lubricant ECOLAB USA INC. 2002-05-02 US disclosed
WO-2002020380-A1 A LUBRICANT QUALIFIED FOR CONTACT WITH A COMPOSITION SUITABLE FOR HUMAN CONSUMPTION, A CONVEYOR LUBRICATION METHOD AND APPARATUS ECOLAB INC. (US) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260041094-A1 Compositions Comprising an Antimicrobial Boosting Agent TLR7, MYC, ERG28 ESR1 3004/4885TSHR 1728/4885LMNA 4342/4885
US-12545860-B2 Mannanase variants MAN2A1, MANBA, IDUA ESR1 4832/4885TSHR 3031/4885LMNA 722/4885
US-20260034042-A1 Composition with Improved SPF and UVA Photoprotection TYR, ERG28, CUTA ESR1 2772/4885TSHR 3393/4885LMNA 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.